Repair Biotechnologies, Inc., a Syracuse, N.Y.-based biotechnology company, raised $2.15m in seed funding.
The round was led by Jim Mellon, the billionaire investor and Chairman of Juvenescence Ltd, with participation from Emerging Longevity Ventures, Thynk Capital, and SENS Research Foundation.
The company intends to use the funds to accelerate the preclinical development of its pipeline of drugs targeting thymus regeneration, cancer, and atherosclerosis.
Founded in 2018 by Reason, CEO, and Bill Cherman, Chairman, Repair Biotechnologies is a biotechnology company developing and bringing to the clinic therapies that improve human healthspan through targeting the causes of age-related diseases and aging itself.
It is developing therapies with the goals of regenerating the thymus, treating cancer, and reversing atherosclerosis.